Glycated Albumin and Adverse Clinical Outcomes in Patients With CKD: A Prospective Cohort Study
Mengyao Tang, Anders H. Berg, Hui Zheng, Eugene P. Rhee, Andrew S. Allegretti, Sagar U. Nigwekar, S. Ananth Karumanchi, James P. Lash, Sahir Kalim
Abstract
RATIONALE & OBJECTIVE: ) is widely used to estimate glycemia, yet it is less reliable in patients with chronic kidney disease (CKD). There is growing interest in the complementary use of glycated albumin (GA) to improve glycemic monitoring and risk stratification. However, whether GA associates with clinical outcomes in a non-dialysis-dependent CKD population remains unknown. STUDY DESIGN: Prospective cohort study. SETTING & PARTICIPANTS: 3,110 participants with CKD from the Chronic Renal Insufficiency Cohort study. EXPOSURE: Baseline GA levels. OUTCOME: Incident end-stage kidney disease (ESKD), cardiovascular disease (CVD) events, and all-cause mortality. ANALYTICAL APPROACH: Cox proportional hazards regression. RESULTS: were added to models. LIMITATIONS: measurements were largely unavailable in participants without diabetes. CONCLUSIONS: among patients with coexisting CKD and diabetes. PLAIN-LANGUAGE SUMMARY: in patients with CKD.